Dr. Gulick is Rochelle Belfer Professor in Medicine and Chief of the Division of Infectious Diseases at Weill Cornell Medicine, and Attending Physician at the New York Presbyterian Hospital in New York City. Dr. Gulick’s research interests include designing, conducting and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention and assess antiretroviral agents with new mechanisms of action. He currently serves as Principal Investigator of the Cornell-New Jersey HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG) and the HIV Prevention Trials Network (HPTN), sponsored by the U.S. National Institutes of Health. He also serves as the Co-Chair of the U.S. Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection, Chair of the NIH Office of AIDS Research Advisory Committee (OARAC), a Board Member of the International Antiviral Society-USA, and previously served as a Member and as Chairman of the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA).
At the completion of this educational session, learners will:
- Be aware of new data on HIV treatment strategies, including treatment initiation, and choosing regimens after treatment failure.
- Know about agents in development for HIV treatment.
- Learn about new data on HIV prevention, including outcomes from recent PrEP studies.
This CME activity has approved for
AMA PRA Category 1 Credit™ on March 19, 2019 and will terminate March 18, 2022.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
You must achieve at least 70% correct to receive your CME certificate.
If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0
AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.
Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.
Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
Dr. Roy M. Gulick (Presenter) had no relevant financial relationships to disclose. Dr. Gulick submitted his slides in advance for adequate peer review, and will support his presentation and clinical recommendations with the best available evidence from the medical literature.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; and Merck & Co.
To obtain CME credit for this PRN program, please visit the
PRN Courses Page at the Clinical Education Initiative (CEI) web site. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.
